Resolution criteria

This market resolves to YES if a peer-reviewed scientific paper or official research registry entry (such as ClinicalTrials.gov) is published by December 31, 2027, documenting a neuroimaging study that utilizes Optically Pumped Magnetometer Magnetoencephalography (OPM-MEG) to investigate the effects of psychedelics (e.g., psilocybin, LSD, MDMA) on human subjects in the context of sexual function, behavior, or sexual response.

If by the resolution date, no such study has been published or publicly registered, the market resolves to NO.

Background

OPM-MEG is an emerging, non-invasive neuroimaging technology that uses wearable quantum sensors to measure the brain's magnetic fields with high temporal and spatial resolution. Unlike traditional cryogenic MEG systems, OPM-MEG does not require liquid helium cooling and allows for greater participant movement during scans, making it suitable for more naturalistic research environments.

While psychedelic research has rapidly expanded—utilizing fMRI, PET, and conventional MEG to study brain network connectivity and receptor pharmacology—investigations into the intersection of psychedelics and sexual behavior remain sparse. Current clinical and preclinical studies often focus on psychiatric outcomes such as depression, anxiety, PTSD, and addiction, or general neuroplasticity. This market tracks whether the increased flexibility of OPM-MEG technology will be applied to this specific area of study before the end of 2027.

This description was generated by AI. Review and verify everything here yourself. You can edit, replace, or delete any part of this description, including the resolution criteria. You do not need to trust the AI output.